"FOUR CLASSES OF DRUGS ONLY" NEEDED

13 December 1993

Worldwide, there needs to be only four classifications for availability of pharmaceutical products, according to delegates attending the first International Conference on Pharmaceutical Competence, held in the Netherlands last month.

Discussing the internationalization standardization of drug legislation, delegates said that medicines should be classed as follows: those available on prescription only, those which may only be sold by pharmacists, those which are available through pharmacies and those which are suitable for general sale. Such standardization would facilitate the switching of prescription-only drugs to more liberalized status, save money and ensure that consumers could obtain their medicines conveniently, and with the benefit of a pharmacist's advice.

In order to facilitate such a move, delegates said that an international database of national pharmaceutical scheduling should be established. Among the changes the four classifications would bring for pharmacists would be a requirement for them to have greater access to diagnosis information, and for them to establish their credibility regarding drug products switched from prescription-only to over-the-counter status.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight